Spyre Therapeutics, Inc. (SYRE)

NASDAQ: SYRE · Real-Time Price · USD

101.50

+3.63 (3.71%)

At close: Jul 30, 2026, 4:00 PM EDT

100.26

-1.24 (-1.22%)

After-hours: Jul 30, 2026, 6:10 PM EDT

Spyre Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	97.19	85.72	89.42	188.89	34.86	15.14
Short-Term Investments	644.28	670.81	513.67	150.38	20.85	77.99
Cash & Short-Term Investments	741.47	756.53	603.09	339.28	55.71	93.13
Cash Growth	31.27%	25.44%	77.76%	509.00%	-40.18%	-36.33%
Accounts Receivable	-	-	-	-	0.38	0.82
Other Current Assets	22.49	21.25	5.39	2.25	6.17	4.95
Total Current Assets	763.95	777.78	608.47	341.53	62.26	98.89
Net Property, Plant & Equipment	-	-	-	-	6.65	8.36
Other Long-Term Assets	-	-	0.01	0.33	2.24	2.68
Total Assets	763.95	777.78	608.48	341.86	71.14	109.93

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.69	8.9	0.67	0.9	0.68	3.32
Accrued Expenses	29.16	26.95	27.71	13.11	12.84	14.03
Current Portion of Leases	-	-	-	-	0.63	0.44
Unearned Revenue	-	-	-	-	0.52	2.36
Other Current Liabilities	50.31	22.83	25.68	17.97	-	-
Total Current Liabilities	85.16	58.69	54.06	31.98	14.66	20.14
Long-Term Leases	-	-	-	-	4	4.61
Other Long-Term Liabilities	7.98	3.86	36.62	41.31	2.18	1.23
Total Long-Term Liabilities	7.98	3.86	36.62	41.31	6.18	5.84
Total Liabilities	93.14	62.55	90.68	73.29	20.84	25.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Preferred Stock	155.82	155.82	155.82	184.93	-	-
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	1,712	1,686	1,334	763.19	475.97	425.77
Accumulated Other Comprehensive Income	-0.77	0.87	0.18	0.3	-0.05	-0.02
Retained Earnings	-1,197	-1,128	-972.43	-764.41	-425.62	-341.81
Minority Interest	-	-	-	84.56	-	-
Shareholders' Equity	670.81	715.24	517.8	184.02	50.31	83.94
Total Liabilities & Equity	763.95	777.78	608.48	341.86	71.14	109.93

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	-	0	0	0	4.63	5.04
Net Cash (Debt)	741.47	756.53	603.09	339.28	51.08	88.08
Net Cash Growth	31.27%	25.44%	77.76%	564.18%	-42.01%	-37.45%
Net Cash Per Share	7.94	11.81	12.82	49.19	-	-
Book Value	670.81	715.24	517.8	184.02	50.31	83.94
Book Value Per Share	7.19	11.17	11.01	26.68	-	-
Tangible Book Value	670.81	715.24	517.8	184.02	50.31	83.94
Tangible Book Value Per Share	7.19	11.17	11.01	26.68	-	-

SEC Filings: 10-K · 10-Q